Hepatitis D

by | Dec 10, 2025 | Blog | 0 comments

Here at LiverRight, we diagnose and treat all forms of Hepatitis in adults, in all 50 staters + DC.

And there could and should be better outcomes in HDV.

The hepatitis delta virus (HDV) is a unique, subviral infectious agent that causes the most severe form of viral hepatitis in humans. It is a “defective” or “satellite” virus because it requires the presence of the hepatitis B virus (HBV) to complete its life cycle and transmit infection.

Here’s a summary of the main points from the Yale School of Medicine article titled “Research Highlights Need To Increase Screening and Treatment of Hepatitis Delta Virus” by Joseph Lim, MD of Yale — and broader context on HDV from related sources.

🔎 What the Yale article says

  • The article emphasizes a significant need to increase both screening and treatment for HDV.
  • The impetus: many people with chronic Hepatitis B (HBV) may also harbor HDV — but HDV is often under-recognized because screening is infrequent or inconsistent.
  • Increased awareness and systematic screening are critical to identifying HDV infections early, which can enable closer monitoring or referral for specialized care / clinical trials — especially as new therapies are emerging.

⚠️ Why HDV is Important & Often Missed

  • HDV is a “satellite” or “defective” virus — it requires HBV (Hepatitis B virus) to enter cells and replicate.
  • When co-infection (HBV + HDV) occurs — or when someone with chronic HBV becomes superinfected with HDV — disease tends to be far worse than HBV alone. HDV accelerates liver fibrosis, increases risk of cirrhosis, hepatocellular carcinoma (liver cancer), and liver-related mortality.
  • Despite seriousness, HDV remains underdiagnosed — in large cohorts of HBV-positive individuals, only a minority get screened for HDV.

🧪 Recommend Screening & Testing

Because risk-based screening (only testing those with traditional “risk factors”) misses many HDV cases, many experts now argue for a universal screening approach — i.e., test all patients who test positive for HBV surface antigen (HBsAg) for HDV:

  • According to the updated guidance by Chronic Liver Disease Foundation (CLDF), screening should begin with an anti-HDV antibody test (to detect past or present exposure).
  • If the anti-HDV test is positive, follow-up with quantitative HDV RNA testing (to confirm active infection).
  • Some labs now support reflex testing — automatically performing HDV screening when HBV surface antigen is identified — and this dramatically increases detection. For example, one study saw screening rates increase from ~2% to ~93% under reflex testing.

💊 Treatment & Future Outlook

  • Treatment for chronic HDV has been challenging. Historically, off-label use of pegylated interferon (Peg-IFN) was the main option — but responses are suboptimal and relapse is common.
  • However — new antiviral agents are in development (some already available outside the U.S.) — including entry inhibitors (e.g. Bulevirtide), prenylation inhibitors (e.g. Lonafarnib), novel interferons, RNA-based therapies, monoclonal antibodies, and more.
  • As these progress through trials, the need for better detection (screening + diagnosis) becomes even more urgent, so patients can be referred to care or studies in time.

📌 Key Recommendations

  1. Expand HDV screening — not just risk-based, but ideally universal for all HBV surface antigen–positive individuals.
  2. Increase clinician awareness — many providers don’t routinely think of HDV, especially outside specialized hepatology settings.
  3. Ensure access to confirmatory testing — antibody screening must be followed by RNA testing for active infection, but RNA assays are not always easy to get.
  4. Link identified patients to care or clinical trials — as newer, better-tolerated antiviral therapies become available.
  5. Public health & surveillance efforts — gather more accurate data on how common HDV really is (prevalence is poorly understood) and support outreach/education.

🎯 Why This Matters

  • HDV co-infection dramatically worsens outcomes versus HBV alone — faster progression to fibrosis, higher risk of cirrhosis and liver cancer, increased mortality.
  • Without systematic screening and better treatment access, many people with HDV will remain undiagnosed until advanced liver disease — a major missed opportunity for prevention or early intervention.
  • The landscape is shifting: with emerging therapies and updated expert guidance, now is a critical moment to close the screening/treatment gap for HDV.